13F Holdings
中文EN

CVM CEL SCI CORP

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 725363 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.9%
TTM EPS YoY81.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-252.5%
ROA-108.9%
ROIC (approx.)-364.5%
Asset turnover—

Leverage & solvency

Liabilities / assets48.7%
Debt / equity0.00x
Current ratio1.48x
Interest coverage-50.08x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-28.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue—————
R&D expense$15.89M$18.16M$22.47M$25.36M$23.11M
SG&A expense$8.92M$8.19M$9.00M$10.71M$13.09M
Operating income-$24.81M-$26.35M-$31.48M-$36.06M-$36.19M
Interest expense$649,000$746,000$675,416$1.08M—
Net income-$25.41M-$26.92M-$32.37M-$36.70M-$36.36M
EBITDA-$22.75M-$24.22M-$29.36M-$34.09M-$35.75M
EPS (basic)———-0.87-0.90
EPS (diluted)-6.27-15.31-0.73-0.87-0.90
Weighted avg. shares (diluted)4.06M1.80M44.48M43.15M40.69M
Banking
Net interest income-$648,944-$745,673—-$1.08M-$1.15M
Balance sheet
Cash & equivalents$10.95M$4.74M$4.15M$22.67M$36.06M
Short-term investments———$0$6.15M
Receivables———$0$54,922
Inventory—$1.02M$2.25M$2.00M$2.01M
Current assets$11.60M$6.06M$6.92M$25.44M$45.27M
PP&E, net$6.08M$8.13M$10.19M$11.89M$13.66M
Intangibles$119,856$165,492$197,704$212,201$275,866
Total assets$28.16M$26.99M$30.53M$50.52M$75.87M
Current liabilities$5.13M$4.62M$5.59M$4.66M$3.94M
Short-term debt$2.27M————
Long-term debt$5.68M————
Total debt$7.96M————
Total liabilities$12.20M$14.12M$17.31M$18.36M$19.34M
Shareholders' equity$15.96M$12.87M$13.21M$32.16M$56.53M
Net debt-$3.00M————
Shares outstanding8.02M2.13M47.42M43.45M43.21M
Cash flow statement
Operating cash flow-$17.12M-$18.81M-$22.85M-$18.24M-$18.79M
Capital expenditure$38,109$94,875$361,892$637,892$9.02M
Free cash flow-$17.16M-$18.91M-$23.21M-$18.88M-$27.80M
Investing cash flow-$38,109-$108,086-$372,262$5.49M-$15.18M
Financing cash flow$23.37M$19.51M$4.69M-$638,426$54.52M
Depreciation & amortization$2.06M$2.13M$2.11M$1.98M$447,000
Stock-based compensation$1.91M$4.27M$6.29M$11.39M$13.69M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.